MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

REGENXBIO Inc

Abrir

SetorSaúde

8.95 0.45

Visão Geral

Variação de preço das ações

24h

Atual

Mín

8.74

Máximo

9.3

Indicadores-chave

By Trading Economics

Rendimento

8.4M

-51M

Vendas

-3M

21M

EPS

-1.01

Margem de lucro

-241.284

Funcionários

353

EBITDA

17M

-38M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+253.26% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

37M

334M

Abertura anterior

8.5

Fecho anterior

8.95

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bullish Evidence

REGENXBIO Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

22 de abr. de 2025, 09:30 UTC

Principais Notícias

Trump's FDA Sends a Bullish Signal to Biotech -- Heard on the Street -- WSJ

Comparação entre Pares

Variação de preço

REGENXBIO Inc Previsão

Preço-alvo

By TipRanks

253.26% parte superior

Previsão para 12 meses

Média 32.5 USD  253.26%

Máximo 50 USD

Mínimo 12 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para REGENXBIO Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

11 ratings

10

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

7.82 / N/ASuporte e Resistência

Curto Prazo

Very Strong Bullish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Bullish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre REGENXBIO Inc

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.